Atherogenic dyslipidemia as evidenced by the lipid triad: Prevalence and associated risk in statin-treated patients in ambulatory care

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2833-2839

  Bestehorn, Kurt ^a,b   Smolka, Wenefrieda ^b   Pittrow, David ^a   Schulte, Helmut ^c   Assmann, Gerd ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MSD Sharp and Dohme GmbH   (Germany)

^c Assmann Stiftung fur Pravention   (Germany)

Author keywords

Atherogenic dyslipidaemia; Hyperlipidaemia; Nicotinic acid; Primary and secondary prevention; Primary care; Prognosis; Risk; Score; Statins; Treatment

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; AMBULATORY CARE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; DYSLIPIDEMIA; FEMALE; GERMANY; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK ASSESSMENT; RISK REDUCTION;

ADULT; AGED; AMBULATORY CARE; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RISK FACTORS; TRIGLYCERIDES;

EID: 78449246743     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.532088     Document Type: Article

References (41)

1. Grundy SM. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am J Cardiol 1995;75:45B-52B
2. Shepherd J, Betteridge J, Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005;21:665-82
3. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49
4. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;51:1512-24
5. Sniderman AD, Jungner I, Holme I, et al. Errors that result from using the TC/ HDL-C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 2006;259:455-61
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Ass 2001;285:2486-97
7. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91
8. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-26
9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
10. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Brit Med J 2003;326:1423-30
11. Lee JMS, Choudhury RP. Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart 2007;93:559-64
12. American Diabetes Association (ADA). Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27:S68-71
13. Abildstrom SZ, Rask-Madsen C, Ottesen MM, et al. Impact of age and sex on sudden cardiovascular death following myocardial infarction. Heart 2002; 88:573-8
14. Norgren L, Hiatt W, Dormandy J, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl. 1):S1-S75 (Pubitemid 46068992)
15. Assmann G, Benecke H, Neiss A, et al. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006;13:776-83
16. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97
17. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-28
18. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-15
19. Assmann G, Schulte H, Cullen P, et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Invest 2007;37:925-32
20. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
21. Maccubbin D, Mitchel Y, Sirah W, et al. Lipid-altering efficacy and tolerability of extended-release niacin/laropiprant in patients with dyslipidemia. Presentation at the Annual Congress of the European Society of Cardiology, Vienna, 2007
22. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and toler-ability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008; 62:1959-70
23. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8
24. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipo-proteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
25. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglyc-erides and risk of cardiovascular events in women. JAMA 2007;298:309-16
26. Mora S, Rifai N, Buring JE, et al. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001
27. Pittrow D, Pieper L, Klotsche J, et al., eds. DETECT. Ergebnisse einer klinisch-epidemiologischen Querschnitts- und Verlaufsstudie mit 50.000 Patienten in 3.000 Hausarztpraxen. München, Elsevier, Oktober 2007;
28. Pittrow D, Stalla GK, Zeiher AM, et al. [Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care]. Med Klin (Munich) 2006;101:635-44
29. Alsheikh-Ali AA, Lin JL, Abourjaily P, et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007;100:1499-501
30. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109:42-6
31. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-81
32. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78
33. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8
34. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008;101(8A):58B-62B
35. Kamanna VS, Vo A, Kashyap ML. Nicotinic acid: recent developments. Curr Opin Cardiol 2008;23:393-8
36. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114
37. Paolini JF, Mitchel YB, Reyes R, et al. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial. Int J Clin Pract 2008;62:896-904
38. Kamal-Bahl SJ, Burke TA, Watson DJ, et al. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin 2008;24:1817-21
39. Belsey J, de Lusignan S, van Vlymen J, et al. Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy. Curr Med Res Opin 2008;24:2703-9
40. European Medicines Agency (EMA). Tredaptive 1000 mg/20 mg modified-release tablets. Summary of Product Characteristics. 25 January 2009. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000889/WC500042216.pdf [Last accessed 22 October 2010]
41. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008;5:319-35